RADIORx’s compounds affect the vascular microenvironment through the selective release of oxidants such as the free radical nitric oxide or NO.
RADIORx is a Silicon Valley-based discovery and development company that has developed a comprehensive portfolio of proprietary NASA-derived molecules with novel mechanisms of action.
RADIORx is currently developing therapies for patients with different types of cancer. For further information about these treatments please visit our For Patients page.
With the precision-guided accuracy of a smart bomb, RRx-001-erythrocytes target the hypoxic microenvironment in cancer and other diseases, potentiating a therapeutic response on site and sparing normal tissue
RRx-001 has the potential to resensitize tumors to failed chemotherapy, turning back the clock and resetting the cancer timeline
RADIORx has expanded its global footprint with strategies to treat orphan diseases such as sickle cell disease and malaria
About Clinical Trials
Meet Our Team
800 W El Camino Real, Suite 180
Mountain View, CA 94040